RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR T-Cell booster aims to stop leukemia relapse
Disease control Recruiting nowThis study tests whether a second type of CAR T-cell therapy, targeting CD22, can extend remission in people with B-cell acute lymphoblastic leukemia who have no signs of cancer after initial CD19 CAR T-cell treatment. About 20 children, adolescents, and adults will receive the m…
Matched conditions: RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New CAR t-cell combo aims to control aggressive leukemia
Disease control Recruiting nowThis study tests a CAR T-cell drug called brexucabtagene autoleucel in 40 adults with B-cell acute lymphocytic leukemia that has come back or is hard to treat. Participants first receive standard chemotherapy drugs to reduce cancer, then get the CAR T-cells. The goal is to see if…
Matched conditions: RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…
Matched conditions: RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Off-the-Shelf CAR-T cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase study tests a new "universal" CAR-T cell therapy (CT1190B) for people aged 12-75 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The therapy is made from donor cells, so it can be given without needing the patie…
Matched conditions: RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for tough leukemia: CAR t cell trial opens for adults
Disease control Recruiting nowThis study is testing a new type of immunotherapy called CAR T cells for adults (ages 18-75) with a hard-to-treat blood cancer called acute lymphoblastic leukemia (ALL) that has come back or not responded to standard treatments. The treatment involves taking a patient's own immun…
Matched conditions: RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: King Faisal Specialist Hospital & Research Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New gene therapy injection shows promise for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new gene therapy called KSV01 for patients with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The study will enroll 30 adults aged 18 to 80 to check if the treatment is safe and tolerable, and to…
Matched conditions: RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC